CareLit · DOI-Nachweis · Osteologie
T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
DOI 10.1055/s-0039-3402889
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE. Michael Lewiecki, Peter R. Ebeling, E Hesse, N Napoli, Daria B. Crittenden, M Rojeski, W Yang, C Libanati, S Ferrari
ZeitschriftOsteologie
Ausgabe01/2020
Jahrgang / SeitenJg. 29
Kernaussage aus der Literatur
Abstract-Vorschau
T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
Zitieren
Zitierempfehlung
E. Michael Lewiecki, Peter R. Ebeling, E Hesse, N Napoli, Daria B. Crittenden, M Rojeski, W Yang, C Libanati, S Ferrari (2020) T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial. Osteologie, 29 (01). https://doi.org/10.1055/s-0039-3402889
Mit CareLit weiterarbeiten